Debrisoquine oxidation phenotype and susceptibility to lung cancer.
作者信息
Boobis A R, Davies D S
出版信息
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
Abstract
摘要
相似文献
1
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
2
Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Br J Clin Pharmacol. 1990 Jan;29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x.
3
Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
Biomed Pharmacother. 1991;45(8):359-62. doi: 10.1016/0753-3322(91)90066-3.
4
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219.
5
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Genet Epidemiol. 1989;6(4):517-24. doi: 10.1002/gepi.1370060406.
6
Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry.
Biomed Environ Mass Spectrom. 1988 Jan 15;15(2):63-6. doi: 10.1002/bms.1200150202.
7
Debrisoquine metabolism and lung cancer risk.
Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):41-8.
8
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
Br J Clin Pharmacol. 1991 May;31(5):533-6. doi: 10.1111/j.1365-2125.1991.tb05575.x.
9
Polymorphic oxidation of debrisoquine in lung cancer patients.
Eur J Cancer. 1991;27(2):158-61. doi: 10.1016/0277-5379(91)90477-u.
10
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
引用本文的文献
1
Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.
Environ Health Perspect. 1996 May;104 Suppl 3(Suppl 3):557-62. doi: 10.1289/ehp.96104s3557.
2
DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
3
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
4
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Br J Clin Pharmacol. 1986 Dec;22(6):739-43. doi: 10.1111/j.1365-2125.1986.tb02969.x.
5
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
Br J Clin Pharmacol. 1987 Dec;24(6):827-9. doi: 10.1111/j.1365-2125.1987.tb03254.x.
6
Diurnal effects on debrisoquine hydroxylation phenotyping.
Eur J Clin Pharmacol. 1988;35(4):441-2. doi: 10.1007/BF00561381.
7
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.
Clin Pharmacol Ther. 1988 Oct;44(4):431-5. doi: 10.1038/clpt.1988.176.
8
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Klin Wochenschr. 1988;66 Suppl 11:87-97.
9
The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Genet Epidemiol. 1989;6(4):517-24. doi: 10.1002/gepi.1370060406.
10
Debrisoquine metabolism and genetic predisposition to lung cancer.
Br J Cancer. 1989 May;59(5):686-7. doi: 10.1038/bjc.1989.142.
Zotero 插件